| abstract |
The present invention relates to novel potassium channel modulators and their use in the preparation of pharmaceutical compositions. Furthermore, the present invention relates to diseases or disorders associated with the activity of potassium channels, specifically respiratory diseases, epilepsy, convulsions, vasospasm, coronary spasms, renal disorders, polycystic kidneys, bladder spasms, urinary incontinence, bladder Drainage disorder, irritable bowel syndrome, gastrointestinal disorder, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina, coronary heart disease, traumatic brain injury, mental disorder, schizophrenia, anxiety, Depression, dementia, memory impairment and attention deficit disorder, Alzheimer's disease, dysmenorrhea, narcolepsy, Raynaud's disease, intermittent claudication, Sjogren's syndrome, migraine, arrhythmia, hypertension, abdominal attack, myotonic dystrophy, dry mouth, type II It is intended for pharmaceutical compositions useful for the treatment or alleviation of diabetes, hyperinsulinemia, premature birth, alopecia, cancer, immunosuppression or pain. |